Skip to main content

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Working Towards a Better Future for Bladder Cancer Patients

  • Bladder cancer is still the sixth most prevalent cancer in the U.S. in 2021
  • The total number of new bladder cancer cases is expected to reach 83,730, with deaths totaling 17,200 this year
  • Imagin Medical Inc. is hoping to offer a better standard of care for bladder cancer patients with its i/Blue Imaging System(TM) that improves visualization for resection, potentially lowering recurrence rates

According to American Cancer Society statistics, the number of cases of all types of cancer this year will total almost 1.9 million, with 608,570 deaths, or approximately 5,200 new cases and 1,670 deaths per day (https://ibn.fm/eDdCz). Of those numbers, bladder cancer remains the sixth most prevalent form of cancer in the United States, with an estimated 83,730 (4.4% of total) new cases and 17,200 (2.8% of total) estimated deaths in 2021 and a greater than 50% recurrence rate. The five-year relative survival rate (2010-2016) was reported at 77% – meaning that only 77% of diagnosed patients survived five years after diagnosis (https://ibn.fm/Y9NoK).

One company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is looking to disrupt the industry, changing how cystoscopies for bladder cancer are performed, with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. The company’s i/Blue Imaging System(TM) is a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.